Office of Science and Technology Center for Devices and Radiological Health, FDA William A. Herman eHealth Technologies and the FDA.

Slides:

Advertisements

Similar presentations

Development Cycle of Medical Devices: A Path of Opportunities for Information Professionals Donna Gay Pharma & Health Tech Div, SLA 2007 Spring Meeting.

Advertisements

Investigational Device Exemption (IDE) Overview for IRBs

Medical Device Law. FDA FDA Regulated Devices From the Beginning Hubbard Electrometer Cases Magnetic Healing Cases Original Law Required Proof of Harm.

BME-IDEA Workshop, September 28, 2005

Regulatory Pathway for Platform Technologies

Entering the US Market: Medical Devices

Investigational Device Exemptions 21 CFR Part 812

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

Overview of FDA Device Regulations

Regulation of Medical Devices Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation.

Barbara Gibson, MS, RN, CCRC, CIP, CHRC Regulatory Affairs Officer Vanderbilt Human Research Protection Program.

Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

Humanitarian Device Exemptions (HDE) 101 Elizabeth Hillebrenner, MSE Biomedical Engineer IDE and HDE Program Staff Center for Devices and Radiological.

Strengthening the Medical Device Clinical Trial Enterprise

1 FDA Update - CDRH Markham C. Luke, MD PhD Deputy Director for Clinical Office of Device Evaluation, CDRH, FDA May 15, 2012 NORD Corporate Council.

POZNAŃ SUPERCOMPUTING AND NETWORKING CENTER Center of e-Infrastructure Center of e-Infrastructure Center for R+D in ICT and their applications POZMAN.

Introduction to Regulation

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.

What Do Toxicologists Do?

Special Topics in IND Regulation

Emerging Forms of Evidence in Assessing Regenerative Medicine Linda F. Hogle,Ph.D. Dept. Medical History and Bioethics University of Wisconsin School.

Medical Devices Approval Process

CDRH Software Regulation

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.

Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.

1 THE UNIQUE ROLES OF IRB IN MEDICAL DEVICE CLINICALL TRIAL Chiu Lin, Ph.D. CITI, May, 2009 CITI, May, 2009.

Device Research Presented by Marian Serge, R.N.. Goals Identify devices Recognize difference between significant risk (SR) and non- significant risk (NSR)

Prof. Moustafa M. Mohamed Vice dean Faculty of Allied Medical Science Pharos University in Alexandria Development and Regulation of Medical Products (MEDR-101)

Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.

The Medical Device Pathway as a Legal Onramp for Futuristic Persons THE FUTURE T HE M EDICAL D EVICE P ATHWAY AS A L EGAL.

REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,

Medical Devices IRB Determination IRB Member Continuing Education.

Biomedical Research.

Compliance with FDA Regulations: Collecting, Transmitting and Managing Clinical Information Dan C Pettus Senior Vice President iMetrikus, Inc.

Integrated Biomedical Information for Better Health Workprogramme Call 4 IST Conference- Networking Session.

1 CONSENSUS STANDARDS OIVD WORKSHOP April 22-23, 2003 Rockville MD Ginette Y. Michaud, M.D. OIVD.

Introduction to Medical Device Problem Reporting Under the Saudi FDA January 2008 Joel J. Nobel, Founder & President Emeritus.

Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.

Celeste F. Bové, M.A., CCC-A Senior Science Policy Analyst Office of Science Coordination & Communication Food and Drug Administration FDA Participation.

The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.

Module C FDA Regulations Regulatory Documents Patricia E. Koziol 1Module C Final Version 10-apr-2010.

Public Health and Risk Assessment (2nd of 10 Lectures on Toxicologic Epidemiology) Michael H. Dong MPH, DrPA, PhD  readings.

Utah Life Science Summit Nov Phil Triolo, PhD RAC President, Phil Triolo and Associates LC.

Nanotechnology - USDA - 18 Nov 2002 REGULATORY CONSIDERATIONS FOR NANOTECHNOLOGY IN PUBLIC HEALTH FOOD AND DRUG ADMINISTRATION Norris E. Alderson, Ph.D.

FDA Regulation Economically Harmful & Morally Indefensible.

UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.

Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.

HUD and Emergent Use Walter Kraft. Device Classification Significant risk – Often involve an invasive procedure for implantation or use – Requires IDE.

Human Specimen Repositories Requirements of 21 CFR Parts 50 & 56 PRIM & R May 5, 2004 Sally A. Hojvat, Ph.D. Director of Microbiology Devices Office of.

1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.

GCP AND MEDICAL DEVICES

Division of Cardiovascular Devices

Regulatory– Terms & Definitions רגולציה - מונחים והגדרות

Premarket Notification 510(k) process

How to Put Together an IDE Application

FDA Perspective on Cardiovascular Device Development

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

The Current PMA Requirements

American Society for Quality Region 5 Quality Conference

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

FDA-CDRH in the Next Decade A Vision for Change

Implantable Medical Devices: Accelerating Standards Development to Streamline Regulation Joshua Price | August 2,

Linda M. Chatwin, Esq. RAC Business Manager, UL LLC

Patient Involvement in the Development and Safe Use of

Opening an IND: Investigator Perspective

Collaborative Smart House Environment Computer Science Department University of Cyprus Contact: Christodoulou Eleni.

Research, Experimentation, & Clinical Trials

Regulatory Perspective of the Use of EHRs in RCTs

Presentation transcript:

Office of Science and Technology Center for Devices and Radiological Health, FDA William A. Herman eHealth Technologies and the FDA

CDRH TECHNOLOGY FORECAST Computer-related Technology Computer-related Technology Molecular Medicine Molecular Medicine Home- and Self-care Home- and Self-care Minimally Invasive Procedures Minimally Invasive Procedures Device/Drug Products Device/Drug Products Organ Replacements and Assists Organ Replacements and Assistshttp:// Emerging Technology Trends

Robert AbodeelyJames Allen Clement Bezold Pfizer - MTGAMA Institute for Alternative Futures Stephen P. BruttigJoseph F. Coates Gilbert B. Devey U.S. ArmyCoates and Jarrett NSF Henry S. EdenDon Giddens Harry Handlesman NIHGa. Inst. Of Tech. AHCPR Peter KatonaIan H. Leverton Barbara McNeil Whitaker FoundationKaiser-Permanente Harvard University Anthony J. MontagnoloRobert M. Nerem Charles H. Swanson ECRI Ga. Inst. Of Tech. Medtronic Survey Participants

Medical Device Technology Drivers Demographic trends Economic trends Technology trends

Computer-related device trends Substantial new product development 5-10 yrs Substantial new product development 5-10 yrs Integrated patient medical information systems Integrated patient medical information systems Smart cards Smart cards Computer-aided medical decisionmaking Computer-aided medical decisionmaking Smart artificial organ implants Smart artificial organ implants Miniaturized biosensors & sensor fusion Miniaturized biosensors & sensor fusion Customized microprocessor devices Customized microprocessor devices

Homecare technology trends Substantial new product development 5-10 yrs Substantial new product development 5-10 yrs Limited expectations for advanced technologies Limited expectations for advanced technologies Monitoring -- blood, urine, drug concentrations Monitoring -- blood, urine, drug concentrations Simplified drug delivery systems Simplified drug delivery systems Telemedicine Telemedicine Smart devices Smart devices

Home Care Technologies for the 21 st Century NSF-FDA Workshop NSF-FDA Workshop participants participants - Industry - Academia - Academia - Government - Government - Clinicians - Clinicians - Providers - Providers

21 st Century Home Care Technology Prevention-oriented devices Prevention-oriented devices Consumer health model Consumer health model Noninvasive sensors Noninvasive sensors Smart devices Smart devices Customized products, flexible configurations Customized products, flexible configurations Data analysis tools for medical decisions Data analysis tools for medical decisions Electronic patient records Electronic patient records Wearable products Wearable products Wireless net-linked systems Wireless net-linked systems

US Food & Drug Administration Center for Drugs Center for Food Safety and Applied Nutrition Center for Biologics Center for Veterinary Medicine Center for Devices and Radiological Health National Center for Toxicological Research Office of Regional Affairs

CDRH Focus Ensuring the safety and effectiveness of medical devices

FDAs Mandate for Regulation Medical Device Amendments (1976) Regulations implementing FD&C Act - Title 21 Code of Federal Regulations (21CFR) Parts 800 – 1299 Safe Medical Devices Act (1990) FDA Modernization Act (1997)

What is a medical device? Diagnosis, cure, mitigation, treatment or prevention of disease or condition Affects the structure and function of the body Does not achieve intended use through chemical reaction Is not metabolized

Device Classification 1700 generic types of devices Three Classes - Class I - Class II - Class III intended use; intended user Classification determines extent of regulatory control

Device Classification Class I - General Controls Class II - General Controls and Special Controls Class III - General Controls and Premarket Approval Risk Low Medium High

Premarket approval – 510k Marketing for first time, or significant change to existing device Demonstration of Substantial Equivalence (SE) to legally marketed device in U.S. SE means As safe and as effective - engineering - clinical outcome

Premarket approval – PMA Only applies to Class III devices - New device - Device found not substantially equivalent Proof of safety and effectiveness with clinical data Investigational Device Exemption (IDE) may be desired or required

Investigational Device Exemption Used for clinical trials Significant risk devices Protection of human subjects Allows sponsor to recoup R&D costs

FDAs Framework -- The traditional strategy Regulatory gatekeeper Unilateral responsibilities Reactive orientation

FDAs Framework -- The emerging strategy Multifaceted, information-based strategy Collaborative multi-party harmonization Anticipatory orientation

eHealth Technology Issues Whats a Device? Whats a Device? Labeling Labeling Smart Devices Smart Devices Tele-health Tele-health Interacting Systems of Devices Interacting Systems of Devices Architectural Considerations Architectural Considerations Environmental Factors Environmental Factors

Action Groupings Public health issues NEGLIGIBLESIGNIFICANT Regulatory mandate NEGLIGIBLE SIGNIFICANT NO ACTION EDUCATION INFORMATION COLLABORATIONS MINIMALISM POLICY REQUIREMENTS - NEW - UPDATED